Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy by Estilo, Cherry L. et al.
Osteonecrosis of the Maxilla and Mandible in Patients with Advanced
Cancer Treated with Bisphosphonate Therapy
CHERRY L. ESTILO,a CATHERINE H. VAN POZNAK,b TIJAANA WILIAMS,a GEORGE C. BOHLE,a
PHYU T. LWIN,a QIN ZHOU,c ELYN R. RIEDEL,c DIANE L. CARLSON,d HEIKO SCHODER,e AZEEZ FAROOKI,f
MONICA FORNIER,g JERRY L. HALPERN,a STEVEN J. TUNICK,a JOSEPH M. HURYNa
aDental Service, Department of Surgery, cDepartment of Epidemiology and Biostatistics, dSurgical Pathology
Service, Department of Pathology, eNuclear Medicine Service, Department of Radiology, fEndocrinology
Service, Department of Medicine, and gBreast Cancer Medicine Service, Department of Medicine, Memorial
Sloan-Kettering Cancer Center, New York, New York, USA; bDepartment of Internal Medicine, University of
Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
Key Words. Bisphosphonate therapy • Pamidronate • Zoledronic acid • Osteonecrosis of the jaw
Disclosure: C.L.E. is a participating investigator in a Novartis-sponsored zoledronic acid trial, CZOL446E2352. C.H.V.P. has served
as a consultant for Amgen and Roche and is a participating investigator in a Novartis-sponsored zoledronic acid trial,
CZOL446E2352. J.M.H. is a consultant to Novartis and a member of the Data Monitoring Committee for the zoledronic acid trial
CZOL446E2352. A.F. is on the speaker’s bureau for Novartis. The content of this article has been reviewed by independent peer
reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of
this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers.
ABSTRACT
Cases of osteonecrosis of the jaw (ONJ) have been re-
ported with an increasing frequency over the past 5
years. ONJ is most often identified in patients with can-
cer who are receiving intravenous bisphosphonate
(IVBP) therapy, but it has also been diagnosed in pa-
tients receiving oral bisphosphonates for nonmalignant
conditions. To further categorize risk factors associated
with ONJ and potential clinical outcomes of this condi-
tion, we performed a retrospective study of patients
with metastatic bone disease treated with intravenous
bisphosphonates who have been evaluated by the Me-
morial Sloan-Kettering Cancer Center Dental Service
between January 1, 1996 and January 31, 2006. We
identified 310 patients who met these criteria. Twenty-
eight patients were identified as having ONJ at presen-
tation to the Dental Service and an additional 7 patients
were subsequently diagnosed with ONJ. Statistically
significant factors associated with increased likelihood
of ONJ included type of cancer, duration of bisphos-
phonate therapy, sequential IVBP treatment with
pamidronate followed by zoledronic acid, comorbid
osteoarthritis or rheumatoid arthritis, and benign he-
matologic conditions. Our data do not support cortico-
steroid use or oral health as a predictor of risk for
ONJ. Clinical outcomes of patients with ONJ were vari-
able with 11 patients demonstrating improvement or
healing with conservative management. Our ONJ expe-
rience is presented here. The Oncologist 2008;13:911–920
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INTRODUCTION
Many cancers in their advanced stages involve the bone
(metastatic bone disease). Bone metastases are associated
with significant morbidity and mortality, including frac-
ture, hypercalcemia of malignancy, spinal cord compres-
sion, and the need for surgery or radiation to bone [1]. These
events are often collectively termed skeletal related events
(SREs). Bisphosphonates are chemical compounds that in-
hibit osteoclast activity. Clinically relevant bisphospho-
nates for cancer treatment include clodronate, ibandronate,
pamidronate, and zoledronic acid. However, only pamid-
ronate and zoledronic acid are approved by the U.S. Food
and Drug Administration for the treatment of osseous tumor
involvement. Randomized controlled clinical trials investi-
gating bisphosphonate therapy have demonstrated a de-
crease in the risk for an SRE by approximately one third.
Hence, bisphosphonate therapy has been incorporated into
the therapy of patients with metastatic bone disease [2].
In 2003, investigators, including our group, reported an
apparent association between bisphosphonate use and the
oral syndrome of osteonecrosis of the jaw (ONJ), where ne-
crotic bone is exposed [3–7]. ONJ is frequently associated
with pain and superinfection. This syndrome has subse-
quently been reported with increasing frequency in the den-
tal and medical literature. The incidence of ONJ in patients
with cancer receiving bisphosphonate therapy for meta-
static bone disease has been estimated to be in the range of
1%–10%, but the true incidence of ONJ in patients with or
without cancer is unknown [8]. We herein present a retro-
spective study of the association between patient, tumor,
and dental characteristics and the development of ONJ in
patients evaluated in the dental clinic at a tertiary cancer
center following i.v. bisphosphonate (IVBP) therapy.
PATIENTS AND METHODS
Following approval by the Memorial Sloan-Kettering Can-
cer Center (MSKCC) Institutional Review Board, patients
treated with IVBP therapy were identified through
MSKCC’s pharmacy database. We performed a retrospec-
tive chart review of patients with a history of multiple my-
eloma (MM), breast cancer (BC), or prostate cancer (PC)
who received IVBP therapy at MSKCC and were evaluated
by the MSKCC Dental Service between January 1, 1996
and January 31, 2006. Using the pharmacy database and the
medical/dental records, patients treated with IVBP therapy
before their first dental visit were identified and categorized
based on their ONJ status at their first dental visit. ONJ was
defined as exposed bone in the maxilla or mandible without
evidence of tumor involvement and without prior irradia-
tion of the affected site to a dose5,500 cGy. An exposed
jaw bone in an area previously treated with 5,500 cGy
represents osteoradionecrosis, a complication of head and
neck cancer radiotherapy that is a separate entity from ONJ.
The study dates of 1996–2006 were selected as they per-
mitted the integration of the multidisciplinary records asso-
ciated with patient care (pharmacy, medical, and dental
records). The study definition of ONJ permits reliable ab-
straction of data using an interdisciplinary approach.
Hence, we used this ONJ definition to look back in time as
far as the record systems were integrated (1996).
The primary objective of the study was to investigate the
association between clinical and pathologic factors and
ONJ development. The ONJ status at the time of the first
dental evaluation was used to define the cohorts in this anal-
ysis. ONJ lesions were retrospectively staged according to
the system proposed by Ruggiero et al. [9]. Patient, tumor,
and dental characteristics were investigated for an associa-
tion with the risk for ONJ development in our population of
patients; those who developed ONJ (ONJ) were compared
with those who did not develop ONJ (ONJ). Information
extracted from the MSKCC health care records and phar-
macy database included demographics, primary cancer di-
agnosis, type and duration of IVBP treatment, social
history, comorbid conditions, type of antineoplastic ther-
apy, history of corticosteroid therapy, and dental health.
The duration of IVBP treatment was defined as the length
of IVBP treatment before an ONJ diagnosis for the ONJ
patients and the length of IVBP treatment before the first
dental visit for the ONJ patients.
The associations between the different patient charac-
teristics, tumor variables, and dental variables and the de-
velopment of ONJ were examined using Fisher’s exact test
for categorical variables and the Wilcoxon rank sum test for
continuous variables. p-values0.05 were considered sta-
tistically significant.
The secondary objectives of this study were to describe
the clinical features, management, and outcome of ONJ in
the cohort of patients who had ONJ before/at the first dental
visit and those who developed ONJ after the first dental
visit.
RESULTS
Demographics
In total, 4,835 patients were treated with IVBP therapy at
MSKCC in the study time period, of whom 310 were re-
ferred to the Dental Service by their medical oncologists for
evaluation and management of various oral and dental com-
plaints including ONJ and other oral lesions as well as den-
tal caries and periodontal disease. Of the 310 patients who
received IVBP treatment prior to their first MSKCC dental
visit, 28 had ONJ (ONJ) and 282 did not.
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The median dental follow-up of the 310 patients was 8
months (range, 0–39 months). Dental follow-up was de-
fined as the time between the first and last dental visits. As
would be expected by the study period, most patients had
been exposed to pamidronate; there were 169 patients
(54.5%) who had received pamidronate as their only IVBP,
77 (24.8%) received zoledronic acid alone, and 64 (20.7%)
had a history of sequential treatment with pamidronate and
zoledronic acid. At the time of the first dental visit, the me-
dian length of IVBP treatment was 11.6 months (range,
0.1–105.7 months). In the ONJ cohort, the median
bisphosphonate therapy duration was 28.8 months (range,
0.9–100.8 months). Figure 1 illustrates the distribution of
the duration of IVBP treatment before ONJ/the first dental
visit among the ONJ and ONJ cohorts.
Association Between Patient, Treatment, and
Dental Parameters and ONJ Development
Table 1 depicts factors univariately associated with the de-
velopment of ONJ. Development of ONJ had a positive sta-
tistically significant association with a primary cancer
diagnosis of BC, sequential IVBP treatment with pamidro-
nate followed by zoledronic acid, the duration of IVBP
treatment, rheumatoid/osteoarthritis, and a nonmalignant
hematologic disorder (e.g., anemias, thalassemias, sickle-
cell trait/disease, coagulation defects). A negative associa-
tion was identified with exposure to 5-fluorouracil,
cyclophosphamide, doxorubicin, methotrexate, corticoste-
roids, and antiangiogenic agents (e.g., bevacizumab, bort-
ezomib, and thalidomide). The occurrence of dental caries
was also found to be negatively associated with ONJ devel-
opment. Periodontal disease and oral hygiene were not
found to be associated with ONJ development.
Clinical Characteristics of ONJ
The clinical features of the 35 patients who had ONJ at their
first dental visit or developed ONJ after their first dental
visit are summarized in Table 2. In all cases, the exposed
bone appeared nonvital, and on being probed was asymp-
tomatic, confirming the necrotic nature of the bone. The
surrounding soft tissues were typically erythematous and
inflamed. The ONJ lesions at initial presentation varied in
size, with most (n  25, 71.4%) of the lesions measuring
1–5 mm in diameter while the rest were1 cm in diameter.
Twenty-two (62.9%) were symptomatic, with the most
common complaints being pain and/or numbness in the af-
fected area, soft tissue swelling, drainage, and tooth mobil-
ity. One patient developed a draining neck fistula
corresponding to the site of ONJ. Two patients developed a
jaw fracture associated with ONJ. The ONJ lesions in three
(8.6%) of the patients were loose and became progressively
mobile over time; these lesions measured at least 1 cm. A
slight majority of the patients (n 18, 51.4%) had a previ-
ous nonhealing dental surgical procedure in the ONJ site.
Spontaneous ONJ was identified in 14 (40%) patients and
occurred in the posterior lingual mandible or the area of the
mylohyoid ridge. The mandible was the more common lo-
cation, being noted in 21 (60%) patients, with 12 (34.3%) in
the maxilla and the rest in both arches.
Radiographic Characteristics of ONJ
Dental radiographs were available for review in 94% (n 
33) of the patients. Radiographic findings in the area of ONJ
ranged from relatively normal bony trabeculation, diffuse ra-
diolucent areas indicating incomplete bony healing in an area
of previous dental surgery, to focal areas of radiolucency, bony
sequestrum, “mothy bone,” or lytic changes. Small areas (1
cm) of nonprogressing ONJ often had normal findings on pan-
oramic radiographs. Likewise, computed tomography scans
showed lytic changes and bony destruction in those with larger
(1 cm) ONJ lesions. Bone scans, obtained for clinical indi-
cations, were available for review in 16 (45.7%) patients and
showed increased uptake in the ONJ site in 62.5% (n 10 of
16) of the cases (Fig. 2).
Histologic Characteristics of ONJ
Thirteen (37.1%) patients underwent conservative bone
biopsy or removal of sharp bony spicules in the area of
ONJ. In all of the 13 bone tissue samples, histological ex-
amination demonstrated fragments of necrotic bone associ-
ated with florid bacterial colonization morphologically
Figure 1. IVBP therapy duration prior to ONJ diagnosis/first
dental visit in ONJ (n 28) and ONJ (n 282) patients.
Abbreviations: IVBP, i.v. bisphosphonate; ONJ, osteone-
crosis of the jaw; ONJ, ONJ present at the first dental visit;
ONJ, ONJ not present at the first dental visit.
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Table 1. ONJ development and its association with various factors
All patients (%) ONJa ONJb p-value
n 310 28 (9.0 %) 282 (91.0)
Primary diagnosis
Breast cancer 134 (43.2) 18 (64.3) 116 (41.1) .01
Multiple myeloma 145 (46.8) 6 (21.4) 139 (49.3)
Prostate cancer 31 (10.0) 4 (14.3) 27 (9.6)
BP
Pamidronate (P) 169 (54.5) 4 (14.3) 165 (58.5)
Zoledronic acid (Z) 77 (24.8) 10 (35.7) 67 (23.8)
P Z 64 (20.7) 14 (50.0) 50 (17.7) .001
Length of BP treatment (mos) before ONJ/first
dental visit
Mean (median) 19.3 (11.6) 34.1 (28.8) 17.8 (11.1)
Range 0.07–105.7 0.9–100.8 0.07–105.7 .001
Rheumatoid arthritis/osteoarthritis
Yes 21 (6.8) 9 (32.1) 12 (4.3) .001
No 289 (93.2) 19 (67.9) 270 (95.7)
Hematologic diseasec
Yes 8 (2.6) 5 (17.9) 3 (1.1) .001
No 302 (97.4) 23 (82.1) 279 (98.9)
5-Fluorouracil
Yes 59 (19.0) 0 (0) 59 (20.9)
No 251 (81.0) 28 (100) 223 (79.1) .004
Cyclophosphamide
Yes 182 (58.7) 5 (17.9) 177 (62.8)
No 128 (41.3) 23 (82.1) 105 (37.2) .001
Doxorubicin
Yes 160 (51.6) 7 (25) 153 (54.3)
No 150 (48.4) 21 (75) 129 (45.7) .005
Methotrexate
Yes 52 (16.8) 0 (0) 52 (18.4)
No 258 (83.2) 28 (100.0) 230 (81.6) .007
Corticosteroid
Yes 261 (84.2) 18 (64.3) 243 (86.2)
No 49 (15.8) 10 (35.7) 39 (13.8) .01
Antiangiogenic agent
Yes 74 (23.9) 2 (7.1) 72 (25.5)
Bevacizumab 7 0 7
Bortezomib (B) 7 0 7
Thalidomide (T) 40 2 38
B T 20 0 20
No 236 (76.1) 26 (92.9) 210 (74.5) .034
Dental caries
Yes 173 (55.8) 7 (25.0) 166 (58.9)
No 119 (38.4) 20 (71.4) 99 (35.1) .001
NAd 18 (5.8) 1 (3.6) 17 (6.0)
(continued)
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consistent with Actinomyces spp. No macrobacterial cul-
tures were available for our review. Although the bony tra-
beculae in each specimen appeared jagged and “moth-
eaten,” associated osteoclasts were generally not observed
in the affected bone. No metastatic tumor was identified.
Soft tissue biopsy consistently revealed inflamed squamous
mucosa or granulation tissue, but none showed any evi-
dence of malignancy (Fig. 3).
Outcome
Resolution of ONJ was defined as complete soft tissue cov-
erage without symptoms and without clinical evidence of
exposed bone, and occurred in three patients. In these three
patients, IVBP therapy was discontinued in one and remain
unchanged in the other two patients. In the patient in whom
IVBP therapy was discontinued, complete resolution of the
maxillary ONJ site occurred after the bone lesion became
increasingly mobile and ultimately exfoliated 2 years fol-
lowing the first dental visit. The underlying tissue appeared
healthy without apparent oroantral communication (Fig. 4).
In the other two patients with ONJ resolution, the ONJ le-
sion resolved after 1 month in one patient (with a history of
35 months of pamidronate for MM) and after 25 months in
the other (with a history of 64 months of pamidronate and
zoledronic acid for metastatic BC). In eight patients, the
ONJ site remained stable and unchanged (range of dental
follow-up, 0–27 months), while 13 others had progression
of ONJ (range of dental follow-up, 3–26 months). Progres-
sion constituted the development of new symptoms, the de-
velopment of ONJ at another site, or an increase in the size
of the ONJ with or without symptoms. Seven patients suc-
cumbed to their cancer during the study period and four
were lost to follow-up.
DISCUSSION
Among the cohort of 310 patients evaluated by the MSKCC
Dental Service, 28 patients had ONJ at their first dental visit
and seven patients developed ONJ thereafter. In order to
most accurately examine the incidence of ONJ, the cohort
must include all patients treated with IVBP therapy in the
same time period. Because the dental cohort represents
10% of the total 4,835 cohort of patients who received
IVBP therapy at our institution, the incidence of ONJ can-
not be precisely determined. Furthermore, the accuracy of
our estimates is limited by the retrospective study design.
However, we can predict that the incidence of ONJ in pa-
tients with MM, BC, and PC treated with IVBP therapy at
MSKCC is at least 0.72% (35 of 4,835).
Table 1. (Continued)
All patients (%) ONJa ONJb p-value
Periodontal diseasee
Yes 260 (83.9) 24 (85.7) 236 (83.7) .64
No 15 (4.8) 2 (7.1) 13 (4.6)
NAd 35 (11.3) 2 (7.1) 33 (11.7)
Presence of symptomatic periodontally compromised teethf
Yes 72 (23.2) 4 (14.3) 68 (24.1) .25
No 210 (67.7) 23 (82.1) 187 (66.3)
NAd 28 (9.0) 1 (3.6) 27 (9.6)
Oral hygiene
Excellent 6 (1.9) 0 (0) 6 (2.1) .96
Good 78 (25.2) 8 (28.6) 70 (24.8)
Fair 142 (45.8) 14 (50.0) 128 (45.4)
Poor 73 (23.6) 6 (21.4) 67 (23.8)
NAd 11 (3.6) 0 (0) 11 (4.0)
aONJ present at first dental visit.
bONJ not present at first dental visit.
cHematologic disease: conditions including anemias, thalassemias, sickle-cell trait/disease, coagulation defects.
dNA: not applicable; data are missing in medical/dental records.
ePeriodontal disease: no: no evidence of radiographic crestal alveolar bone loss; yes: at least 25% radiographic crestal
alveolar bone loss.
fSymptomatic periodontally compromised teeth: yes: pain, tooth mobility, gingival swelling, purulent discharged in areas
with at least 25% radiographic crestal alveolar bone loss; no: absence of above symptoms in areas with at least 25%
radiographic alveolar bone loss.
Abbreviations: BP, bisphosphonate; ONJ, osteonecrosis of the jaw.
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Risk factors associated with the development of ONJ
were examined by association checking analysis and dem-
onstrated a significant positive association between ONJ
development and a primary cancer diagnosis of BC, se-
Table 2. Clinical features of ONJ
Characteristic All patients (%) ONJa ONJ3b
n 35 28 (80%) 7 (20)
Median (range) duration of BP treatment, mosc 26 (1–101) 26 (1–101) 19 (3–55)
Nature of ONJ
Dental extraction/dental implant placement 18 (51.4) 14 (50.0) 4 (57.1)
Spontaneous 14 (40.0) 11 (39.3) 3 (42.9)
Both 3 (8.6) 3 (10.7) 0
Location of ONJ
Maxilla 12 (34.3) 10 (35.7) 2 (28.6)
Mandible 21 (60.0) 16 (57.1) 5 (71.4)
Both 2 (5.7) 2 (7.1) 0
Anterior versus posterior
Anterior 2 (5.7) 1 (3.6) 1 (14.3)
Posterior 32 (91.4) 26 (92.9) 6 (85.7)
Midline torus 1 (2.9) 1 (3.6) 0
Symptomatology
Present 22 (62.9) 19 (67.9) 3 (42.9)
Absent 13 (37.1) 9 (32.1) 4 (57.1)
Size of exposed bone
1 cm 25 (71.4) 18 (64.3) 7 (100)
1 cm 10 (28.6) 10 (35.7) 0
Clinical staging
Stage 1 20 (57.1) 17 (60.7) 3 (42.9)
Stage 2 13 (37.1) 9 (32.1) 4 (57.1)
Stage 3 2 (5.7) 2 (7.1) 0
Bone scan available
Yes 16 (45.7) 15 (53.6) 1 (14.3)
No 19 (54.3) 13 (46.4) 6 (85.7)
Management
Antibiotic therapy 16 (45.7) 15 (53.6) 1 (14.3)
Conservative sequestrectomy/curettage 7 (20.0) 6 (21.4) 0
Chlorhexidine rinse 0.12% 35 (100.0) 25 (89.3) 6 (85.7)
Conservative bone biopsy 13 (37.1) 12 (42.9) 1 (14.3)
Outcome
Resolution 3 (8.6) 2 (7.1) 1 (14.3)
No change in ONJ status 8 (22.9) 7 (25.0) 1 (14.3)
Progression of ONJ 13 (37.1) 11 (39.3) 2 (28.6)
Deceased 7 (20.0) 5 (17.9) 2 (28.6)
Lost to follow-up 4 (11.4) 3 (10.7) 1 (14.3)
Median dental follow-up (range) 15 (0–62) 4 (0–32) 5 (1–30)
aONJ present at first dental visit.
bONJ developed after first dental visit.
cMedian duration of BP treatment at time of ONJ diagnosis.
Abbreviations: BP, bisphosphonate; ONJ, osteonecrosis of the jaw.
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quential therapy with pamidronate and zoledronic acid, the
length of IVBP therapy, rheumatoid arthritis and osteoar-
thritis, and a nonmalignant hematologic disorder. Our co-
hort demonstrated a significant negative association with
exposure to 5-fluorouracil, cyclophosphamide, doxorubi-
cin, and methotrexate. These findings are provocative in
that patients with a history of BC appear to be at greater risk
for ONJ, yet drugs commonly used in the treatment of BC
(doxorubicin, cyclophosphamide, 5-fluorouracil, metho-
trexate) were identified as negative predictors of ONJ risk.
One explanation regarding the relatively higher incidence
of ONJ among BC patients is the fact that BC patients have
a relatively longer life expectancy; hence, their lengths of
bisphosphonate treatment time are longer and their likeli-
hood of exposure to sequential pamidronate followed by
zoledronic acid is higher. Our findings are consistent with
those of others, in which the risk for ONJ in patients with
metastatic cancer is in the range of approximately 1%–10%
[10–12]. However, because of the retrospective nature of
and the small number of cases in our study, the relationship
between these confounding factors cannot be fully ex-
plored. Of note, our analysis indicated a negative associa-
tion between ONJ and exposure to corticosteroid therapy.
Figure 2. Radiographic characteristics of ONJ. (A): Pan-
oramic radiograph of a nonhealing extraction socket showing
progressive bony destruction in the right mandible (arrow).
(B): Panoramic radiograph of spontaneous ONJ showing bony
sequestrum in the left mandible (arrow). (C): Axial view of a
computed tomography scan demonstrating a lytic lesion in the
right body of the mandible (arrow). (D): Anterior view of bone
scan showing increased uptake in the left mandible (arrow).
Abbreviation: ONJ, osteonecrosis of the jaw.
Figure 3. Histologic characteristics of ONJ. (A): Mandibular
bone biopsy showing necrotic bone (solid arrow) with asso-
ciated filamentous bacterial colonies morphologically re-
sembling Actinomyces israelli (dashed arrow) (100
magnification). (B): The “moth-eaten” (oval arrow) appear-
ance of the bone suggests that the Actinomyces bacteria’s role
in this process may be pathogenic (200magnification). (C):
Mandibular gingiva biopsy revealing acute inflammation
(200 magnification). (D): At high power, polymononuclear
neutrophils are evident (diamond arrow) (400 magnifica-
tion). All specimens were stained with hematoxylin and eosin.
Abbreviation: ONJ, osteonecrosis of the jaw.
Figure 4. Clinical characteristics of ONJ. (A): First dental
visit. The maxillary right molar tooth was extracted 1 year
prior. The patient complained of drainage from the area of ex-
posed bone. (B): Six months following the first dental visit.
The size of the ONJ has increased. (C): One year following the
first dental visit. The size of the ONJ continues to grow. (D):
The exposed bone gradually became mobile and subsequently
exfoliated 1 year later.
Abbreviation: ONJ, osteonecrosis of the jaw.
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Although steroid use has long been associated with osteo-
necrosis of the long bones, the role of corticosteroids in the
pathogenesis of osteonecrosis is unclear [13]. Steroids are
routinely incorporated into anticancer therapeutic regimens
and may be administered i.v. or orally. The retrospective
nature of our investigation, like that of others, is limited in
its ability to capture prescriptions filled in the outpatient
setting. ONJ occurred in patients with good oral hygiene
and in the absence of underlying dental or periodontal dis-
ease. Our data do not demonstrate a higher risk for ONJ in
association with poor oral hygiene or the presence of peri-
odontal disease. Our finding is contrary to the hypothesis
that poor oral health (i.e., poor oral hygiene, presence of
dental infection) is a risk factor for the development of ONJ
[11]. An ongoing and planned prospective study will vali-
date or refute this provocative finding. The outcome of ONJ
in our cohort was variable, with only three patients demon-
strating resolution of ONJ. In our experience, and that of
others [15, 19], withholding or decreasing IVBP therapy
did not appear to alter the course of ONJ.
In all bone biopsies in our study, florid bacterial coloniza-
tion was present, with filamentous bacteria morphologically
consistent with Actinomyces. In their histopathological study
of 45 patients with actinomycosis of the jaws in which 26 pa-
tients had bisphosphonate-associated ONJ, Hansen et al.
[14] found Actinomyces in direct contact with bone tissue.
In addition, mixed inflammatory infiltrates with variable
amounts of osteoclasts were typically found in the sur-
rounding medullary spaces. It is currently unclear whether
Actinomyces is actively contributing to ONJ development
or progression or is simply an “innocent bystander”/sec-
ondary phenomenon related to the necrotic bone and anaer-
obic environment. Ongoing prospective studies are
analyzing the bacterial component in gingival crevicular
fluid in order to identify potential risk factors for ONJ de-
velopment.
Our data showed that, among the ONJ patients, the du-
ration of IVBP therapy before ONJ onset was shorter for
those receiving zoledronic acid (median, 8.7 months) than
for those receiving pamidronate alone (median, 44.5
months) or pamidronate plus zoledronic acid (median, 31.5
months). This finding is consistent with other reports [3,
15–19]. This may be explained by zoledronic acid’s consid-
erably higher potency compared with pamidronate [19]. Of
the 28 ONJ patients, 20 had a12-month history of IVBP
therapy. Naturally, these patients were also exposed to
other antineoplastic and supportive medications during this
time frame as well. In our study, there were no definitive
radiographic or histologic pathognomonic findings of
ONJ. In all cases, the diagnosis of ONJ was made based on
clinical assessment. Panoramic radiographs in our patients
were nonspecific and nondiagnostic, which is consistent
with the imaging findings of other investigators. In their
study of patients treated with bisphosphonates who under-
went bone scans, O’Connor et al. [20] found that jaw uptake
on bone scan was not a reliable predictor of ONJ develop-
ment. There was jaw uptake in 92% (12 of 13) of patients
with ONJ and 70% (128 of 183) of patients with no ONJ.
The difference was not significant between the two groups.
However, other investigators have suggested that bone
scans may be able to identify ONJ precursor lesions (Land-
esberg R, personal communication, [22]).
In our experience, approximately 60% of ONJ cases
with bone scans available for review showed increased up-
take in the ONJ site. This is a provocative finding given the
assumption that necrotic bone would show no radiotracer
uptake. However, radiotracer uptake on bone scan is a func-
tion of local perfusion and osteoblast activity. The noted in-
creased uptake in ONJ may not occur in the necrosis, but as
a reactive change in the surrounding bone. The resolution of
the planar whole body bone scans, even when “spot views”
of the head/jaw were obtained, was too poor to distinguish
between the site of necrosis and adjacent or intermixed nor-
mal bone. In addition, on planar images, there is overlap of
the site of necrosis and surrounding bone (two-dimensional
image of a three-dimensional structure). While our data
may not be definitive, they may serve as potential back-
ground data for future studies and aid the clinician in appre-
ciating the protean findings associated with ONJ. Thus, we
continue to search for reliable diagnostic and imaging tech-
niques with which to assess and diagnose ONJ.
There is growing and intensive preclinical evidence
showing that bisphosphonates may exert an antitumor ef-
fect on MM, BC, and PC through inhibition of angiogenesis
[22–25]. Angiogenesis is an essential step in tumorigenesis
[26]. It also plays an important role in wound healing and
bone remodeling [27, 28]. Could an antiangiogenic effect of
bisphosphonate therapy contribute to the development of
ONJ? In our study, 74 patients were treated with the anti-
angiogenic agents bevacizumab, bortezomib, and thalido-
mide. However, out analysis showed a negative association
between the use of these agents and ONJ development. The
date from Aragon-Ching et al. [29] demonstrating a 17%
incidence of ONJ in patients with PC receiving thalido-
mide, bevacizumab, docetaxel, and prednisone in a clinical
trial (zoledronic acid was used as per standard practice)
suggested that the risk for ONJ may be higher with chemo-
therapy regimens that include steroids and antiangiogenic
agents. The high rate of ONJ identified in this prospective
clinical study is provocative given the use of novel thera-
pies; updated results are eagerly awaited.
Given the increasing reports of bisphosphonate-associ-
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ated ONJ and the fact that the indications for bisphospho-
nate therapy are now expanding beyond the management of
tumor-associated bone diseases to include benign meta-
bolic bone diseases, clinicians and patients should be fully
aware of ONJ as a possible treatment-related complication.
ONJ guidelines have been generated by dental, medical,
and bone societies [17, 30–33]. The National Institute for
Dental and Craniofacial Research has generated a research-
funding mechanism to investigate ONJ, and clinical trials
investigating drugs that inhibit osteoclast function and/or
activity have incorporated dental assessments and evalua-
tion of ONJ into the clinical trials. The Southwest Oncology
Group will be launching a prospective registry of patients
with metastatic bone disease treated with IVBP therapy
(S0702) and the German ONJ registry set up in 2004 now
contains data on 600 patients (http://www.nyas.org). Pro-
spective clinical and translational studies are clearly needed
to investigate the pathogenesis of ONJ, to identify the risk
factors for its development, and to develop means for its de-
tection and management.
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